Toward standardized reporting of drug interactions: the READI checklist for anecdotal reports

References

• Aronson JK, Derry S, Loke YK. Adverse drug reactions: keeping up to date. Fundam Clin Pharmacol 2002;16(1):49-56
   Google Scholar
• Harpaz R, Chase HS, Friedman C. Mining multi-item drug adverse effect associations in spontaneous reporting systems. BMC Bioinformatics 2010;11 Suppl 9:S7
   Google Scholar
• Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2014;23(5):489-97
   PubMed Web of Science ®Google Scholar
• Calderón-Ospina C, Bustamante-Rojas C. The DoTS classification is a useful way to classify adverse drug reactions: a preliminary study in hospitalized patients. Int J Pharm Pract 2010;18:230-5
   Google Scholar
• Charrois TL, Hill RL, Vu D, et al. Community identification of natural health product-drug interactions. Ann Pharmacother 2007;41(7):1124-9
   Google Scholar
• EQUATOR network. Available from: www.equator-network.org
   Google Scholar
• Aronson JK. PHARMA: Publishing Histories of Adverse Reactions to Medicaments Anecdotally. online 2003. Available from: www.bmj.com/cgi/content/full/326/7403/1346/DC1?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=1&author1=Aronson&andorexacttitle=and&andorexacttitleabs=and&fulltext=anecdotes&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=date&fdate=1/1/1981&resourcetype=HWCIT [Last accessed 18 April 2009]; and via reference 45
   Google Scholar
• Kelly WN, Arellano FM, Barnes J, et al. International Society for Pharmacoepidemiology; International Society of Pharmacovigilance. Guidelines for submitting adverse event reports for publication. Drug Saf 2007;30(5):367-73
   PubMed Web of Science ®Google Scholar
• Kelly WN, Arellano FM, Barnes J, et al. International Society of Pharmacoepidemiology; International Society of Pharmacovigilance. Guidelines for submitting adverse event reports for publication. Pharmacoepidemiol Drug Saf 2007;16(5):581-7
   PubMed Web of Science ®Google Scholar
• Kelly W, Arellano F, Barnes J, et al. Guidelines for submitting adverse event reports for publication. Recommandations pour la publication des événements indésirables. Thérapie 2009;64(4):289-94
   PubMed Web of Science ®Google Scholar
• Aronson JK. Guidelines and a checklist for reporting suspected adverse drug reactions anecdotally in journals. In: Talbot J, Aronson JK, editors. Stephens’ Detection and Evaluation of Adverse Drug Reactions: Principles and Practice. 6th edition. Oxford: Wiley-Blackwell; 2011. 699-708
   Google Scholar
• Moreno F, Hardin TC, Rinaldi MG, Graybill JR. Itraconazole–didanosine excipient interaction. JAMA 1993;269(12):1508
   Google Scholar
• Puech R, Gagnieu MC, Planus C, et al. Extreme bradycardia due to multiple drug-drug interactions in a patient with HIV post-exposure prophylaxis containing lopinavir–ritonavir. Br J Clin Pharmacol 2011;71(4):621-3
   PubMed Web of Science ®Google Scholar
• Grahame-Smith DG, Aronson JK. Drug interactions. In: The Oxford Textbook of Clinical Pharmacology and Drug Therapy. 3rd edition. Oxford: Oxford University Press; 2002; Chapter 7
   Google Scholar
• Kinoshita S, Kondo K. Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers. Expert Opin Drug Metab Toxicol 2015;11(1):7-14
   PubMed Web of Science ®Google Scholar
• Yang J, Kjellsson M, Rostami-Hodjegan A, Tucker GT. The effects of dose staggering on metabolic drug-drug interactions. Eur J Pharm Sci 2003;20(2):223-32
   PubMed Web of Science ®Google Scholar
• Barnes J. Adverse drug reactions and pharmacovigilance of herbal medicines. In: Talbot J, Aronson JK, editors. Stephens’ Detection and Evaluation of Adverse Drug Reactions: Principles and Practice. 6th edition. Oxford: Wiley-Blackwell; 2011. 645-83
   Google Scholar
• Kammerl MC, Schaefer RM, Schweda F, et al. Extracorporal therapy with AN69 membranes in combination with ACE inhibition causing severe anaphylactoid reactions: still a current problem? Clin Nephrol 2000;53:486-8
   Google Scholar
• Wu JM, Wells EC, Hundley AF, et al. Mesh erosion in abdominal sacral colpopexy with and without concomitant hysterectomy. Am J Obstet Gynecol 2006;194:1418-22
   Google Scholar
• Gerçek A, Ay B, Dogan V, et al. Esophageal balloon dilation in children: prospective analysis of hemodynamic changes and complications during general anesthesia. J Clin Anesth 2007;19(4):286-9
   Google Scholar
• US Congress. Federal Food Drug and Cosmetic Act. Section 201 (321). Definitions (h). 1998. Available from: www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/FDCActChaptersIandIIShortTitleandDefinitions/ucm086297.htm
   Google Scholar
• Kellner CH, Nixon DW, Bernstein HJ. ECT—drug interactions: a review. Psychopharmacol Bull 1991;27(4):595-609
   Google Scholar
• Patra KK, Coffey CE. Implications of herbal alternative medicine for electroconvulsive therapy. J ECT 2004;20(3):186-94
   PubMed Web of Science ®Google Scholar
• Tannenbaum C, Sheehan NL. Understanding and preventing drug-drug and drug-gene interactions. Expert Rev Clin Pharmacol 2014;7(4):533-44
   PubMed Web of Science ®Google Scholar
• Waters NJ. Evaluation of drug-drug interactions for oncology therapies: in vitro–in vivo extrapolation model-based risk assessment. Br J Clin Pharmacol 2014;10.1111/bcp.12563. [Epub ahead of print]
   Google Scholar
• Maeda A, Tsuruoka S, Kanai Y, et al. Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporter 3-transfected cells. Eur J Pharmacol 2008;596(1-3):166-72
   PubMed Web of Science ®Google Scholar
• Hull MW, Montaner JS. Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med 2011;43(5):375-88
   PubMed Web of Science ®Google Scholar
• Capon DA, Bochner F, Kerry N, et al. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan. Clin Pharmacol Ther 1996;60(3):295-307
   PubMed Web of Science ®Google Scholar
• Kajosaari LI, Backman JT, Neuvonen M, et al. Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. Br J Clin Pharmacol 2004;58(4):390-6
   Google Scholar
• Shenfield GM. Oral contraceptives. Are drug interactions of clinical significance? Drug Saf 1993;9(1):21-37
   PubMed Web of Science ®Google Scholar
• Orme ML, Back DJ. Oral contraceptive steroids—pharmacological issues of interest to the prescribing physician. Adv Contracept 1991;7(4):325-31
   Google Scholar
• Clinical Effectiveness Unit of the Faculty of Sexual & Reproductive Healthcare in the UK’s Royal College of Obstetricians and Gynaecologists. Drug Interactions with Hormonal Contraception. 2012.www.fsrh.org/pdfs/CEUguidancedruginteractionshormonal.pdf
   Google Scholar
• Aronson JK. Hormonal contraceptives, oral. In: Meyler’s Side Effects of Drugs – The International Encyclopedia of Adverse Drug Reactions and Interactions. 16th edition. Amsterdam: Elsevier; 2015
   Google Scholar
• Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998;279(9):657-62
   PubMed Web of Science ®Google Scholar
• Gebauer MG, Nyfort-Hansen K, Henschke PJ, Gallus AS. Warfarin and acetaminophen interaction. Pharmacotherapy 2003;23(1):109-12
   PubMed Web of Science ®Google Scholar
• Whyte IM, Buckley NA, Reith DM, et al. Acetaminophen causes an increased International Normalized Ratio by reducing functional factor VII. Ther Drug Monit 2000;22(6):742-8
   PubMed Web of Science ®Google Scholar
• Visser LE, Penning-van Beest FJ, et al. Overanticoagulation associated with combined use of lactulose and acenocoumarol or phenprocoumon. Br J Clin Pharmacol 2004;57(4):522-4
   Google Scholar
• Andersson ML, Lindh JD, Mannheimer B. The impact of interacting drugs on dispensed doses of warfarin in the Swedish population: A novel use of population based drug registers. J Clin Pharmacol 2013;53(12):1322-7
   PubMed Web of Science ®Google Scholar
• Roblek T, Vaupotic T, Mrhar A, Lainscak M. Drug-drug interaction software in clinical practice: a systematic review. Eur J Clin Pharmacol 2015;71(2):131-42
   PubMed Web of Science ®Google Scholar
• Aronson JK. Happy fiftieth birthday, Yellow Cards. [Last accessed 9 December 2014] Available from: www.cebm.net/happy-fiftieth-birthday-yellow-cards
   Google Scholar
• World Health Organization. WHO pilot research project for international drug monitoring. Report of a meeting for investigators, Geneva, 22-27 September 1969; DMO/69.2
   Google Scholar
• Lagier G, Labardens P, Efthymiou M-L, Conso F. Pharmaco-vigilance en milieu hospitalier. In: Centre anti-poisons: accidents thérapeutiques effets secondaires des medicaments. Méthodologie de leur dépistage pharmaco-vigilance a l’hôpital. Lyon: Masson & Cie; 1973. 101-4
   Google Scholar
• Venulet J. Aspects of standardization as applied to the assessment of drug–event associations. Drug Inf J 1984;18(3-4):199-210
   Google Scholar
• Moore N, Montero D, Coulson R, et al. The single case format: proposal for a structured message for the telematic transmission of information on individual case reports in pharmacovigilance. Pharmacoepidemiol Drug Saf 1994;3:157-62
   Google Scholar
• Edwards IR, Lindquist M, Wiholm BE, Napke E. Quality criteria for early signals of possible adverse drug reactions. Lancet 1990;336:156-8
   PubMed Web of Science ®Google Scholar
• Council for International Organizations of Medical Sciences (CIOMS) Working Group V. Current Challenges in Pharmacovigilance: Pragmatic Approaches. Geneva: Council for International Organizations of Medical Sciences; 2001
   Google Scholar
• Venulet J. Informativity of adverse drug reactions data in medical publications. Drug Inf J 1985;19:357-65
   Google Scholar
• Groupe de Travail sur les Bonnes Pratiques de Publication de Cliniques en Pharmacovigilance. Auriche M, Bertrand P, Blay N, et al. Les bonnes pratiques de publication de cas cliniques de pharmacovigilance: commentaires. Commentary. Good practice in publication of case reports in pharmacovigilance. Thérapie 1997;52(2):123-7
   Google Scholar
• Berneker GC, Ciucci AG, Joyce J. Standards for reporting adverse drug reactions. Br Med J (Clin Res Ed) 1983;287(6406):1720
   Google Scholar
• Aronson JK. Anecdotes as evidence. BMJ 2003;326(7403):1346
   PubMed Web of Science ®Google Scholar
• Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ 2006;332:1267-9
   Google Scholar
• Hauben M, Aronson JK. Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade ore. Drug Saf 2007;30(8):645-55
   PubMedGoogle Scholar
• DeBakey L, DeBakey S. The case report. I. Guidelines for preparation. Int J Cardiol 1983;4(3):357-64
   Google Scholar
• DeBakey L, DeBakey S. The case report. II. Style and form. Int J Cardiol 1984;6(2):247-54
   Google Scholar
• Jenicek M. Clinical case reporting in evidence-based medicine. 2nd ed. London: Arnold; 1999
   Google Scholar
• Cohen LG, Rovers JP. Addendum to guidelines for reporting adverse drug reactions. Br Med J (Clin Res Ed) 1988;296(6639):1800
   Google Scholar
• Karch SB. Peer review and the process of publishing of adverse drug event reports. J Forensic Leg Med 2007;14(2):79-84
   Google Scholar
• Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41(4):674-80
   PubMed Web of Science ®Google Scholar
• Scheife RT, Hines LE, Boyce RD, et al. Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support. Drug Saf 2015;38(2):197-206
   PubMed Web of Science ®Google Scholar
• Laganiere S, Biron P. Clinical trials: incomplete reporting of side effects. Curr Ther Res 1979;25:743-6
   Google Scholar
• Venulet J, Blattner R, von Bülow J, Berneker GC. How good are articles on adverse drug reactions? Br Med J (Clin Res Ed) 1982;284(6311):252-4
   Google Scholar
• Hemminki E. Study of information submitted by drug companies to licensing authorities. BMJ 1980;280(6217):833-6
   PubMedGoogle Scholar
• Hibberd PL, Meadows AJ. Information contained in clinical trial reports. J Inf Sci 1980;2:165-8
   Google Scholar
• Aronson JK. Anecdotes as evidence. BMJ 2003;326(7403):1346
   PubMed Web of Science ®Google Scholar
• Kelly WN. The quality of published adverse drug event reports. Ann Pharmacother 2003;37(12):1774-8
   Google Scholar
• Loke YK, Price D, Herxheimer A; The Cochrane Adverse Effects Methods Group. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol 2007;7:32
   Google Scholar
• Stevens AJ, Woodman RJ, Owen H. The effect of ondansetron on the efficacy of postoperative tramadol: a systematic review and meta-analysis of a drug interaction. Anaesthesia 2015;70(2):209-18
   Google Scholar
• Yu J, Ritchie TK, Mulgaonkar A, Ragueneau-Majlessi I. Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review. Drug Metab Dispos 2014;42(12):1991-2001
   PubMed Web of Science ®Google Scholar
• Wald NJ, Morris JK. Teleoanalysis: combining data from different types of study. BMJ 2003;327(7415):616-18
   Google Scholar
• Loke YK. Adverse drug reactions. Br J Clin Pharmacol 2012;73(6):908-11
   Google Scholar
• Floor-Schreudering A, Bouvy ML, Aronson JK, et al. Checklist for standardized reporting of drug-drug interaction management guidelines. Eur J Clin Pharmacol 2014;70(3):313-18
   PubMed Web of Science ®Google Scholar
• Floor-Schreudering A, Movig KLL, Bouvy ML, De Smet PAGM. Exemplary guideline for the management of the interaction between thiazides (and related diuretics) and selective serotonin reuptake inhibitors (SSRIs) or serotonin–norepinephrine reuptake inhibitors (SNRIs). Eur J Clin Pharmacol 2014;70(3 Suppl ESM3):313-18
   Google Scholar
• Edwards IR, Aronson JK. Adverse drug reactions—definitions, classification, diagnosis, management, surveillance. Lancet 2000;356:1255-60
   PubMed Web of Science ®Google Scholar
• Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf 2005;28(10):851-70
   PubMed Web of Science ®Google Scholar
• Ferner RE, Aronson JK. Clarification of terminology in medication errors: definitions and classification. Drug Saf 2006;29(11):1011-22
   PubMed Web of Science ®Google Scholar
• Derry S, Loke YK, Aronson JK. Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med Res Methodol 2001;1:7
   Google Scholar
• Aronson JK, When I. Use a Word … Declarative titles. QJM 2010;103(3):207-9
   Google Scholar
• Tayyareci Y, Acarel E. Acute myocardial infarction associated with disulfiram–alcohol interaction in a young man with normal coronary arteries. Turk Kardiyol Dern Ars 2009;37(1):48-50
   Google Scholar
• Yoganathan K, David L, Williams C, Jones K. Cushing’s syndrome with adrenal suppression induced by inhaled budesonide due to a ritonavir drug interaction in a woman with HIV infection. Int J STD AIDS 2012;23(7):520-1
   PubMed Web of Science ®Google Scholar
• Cohen AM, Hersh WR. A survey of current work in biomedical text mining. Brief Bioinform 2005;6(1):57-71
   PubMed Web of Science ®Google Scholar
• Kostoff RN, Block JA, Stump JA, Pfeil KM. Information content in Medline record fields. Int J Med Inform 2004;73(6):515-27
   PubMedGoogle Scholar
• Aronson JK. Changing beta-blockers in heart failure: when is a class not a class? Br J Gen Pract 2008;58(551):387-9
   Google Scholar
• Aronson JK. From prescription-only to over-the-counter medicines (‘PoM to P’)—time for an intermediate category. Br Med Bull 2009;90:63-9
   Google Scholar
• Aronson JK, When I. Use a Word … Masses and masses. BMJ 2002;324:1521
   Google Scholar
• Smith R. The BMJ, spin, and the stockmarket. BMJ 2000;320(7251):1737
   Google Scholar